These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 23532334

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A.
    PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 5. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
    Zhang J, Huang K, O'Neill KL, Pang X, Luo X.
    Cell Death Dis; 2016 Jun 16; 7(6):e2266. PubMed ID: 27310874
    [Abstract] [Full Text] [Related]

  • 6. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A, Kraft M, Eliasson P, Labi V, Lam EW, Villunger A, Jönsson JI.
    Blood; 2009 Mar 05; 113(10):2302-11. PubMed ID: 19064725
    [Abstract] [Full Text] [Related]

  • 7. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
    Oncogene; 2011 Sep 29; 30(39):4097-106. PubMed ID: 21499301
    [Abstract] [Full Text] [Related]

  • 8. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2013 Feb 15; 73(4):1340-51. PubMed ID: 23243017
    [Abstract] [Full Text] [Related]

  • 9. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.
    Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA.
    Cancer Discov; 2011 Sep 15; 1(4):352-65. PubMed ID: 22145099
    [Abstract] [Full Text] [Related]

  • 10. Genetically defining the mechanism of Puma- and Bim-induced apoptosis.
    Garrison SP, Phillips DC, Jeffers JR, Chipuk JE, Parsons MJ, Rehg JE, Opferman JT, Green DR, Zambetti GP.
    Cell Death Differ; 2012 Apr 15; 19(4):642-9. PubMed ID: 22015606
    [Abstract] [Full Text] [Related]

  • 11. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
    Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J.
    Oncogene; 2009 Jun 18; 28(24):2348-57. PubMed ID: 19421143
    [Abstract] [Full Text] [Related]

  • 12. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
    Chen S, Dai Y, Pei XY, Grant S.
    Mol Cell Biol; 2009 Dec 18; 29(23):6149-69. PubMed ID: 19805519
    [Abstract] [Full Text] [Related]

  • 13. ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells.
    Li DD, Wu XQ, Tang J, Wei XY, Zhu XF.
    Cancer Biol Ther; 2009 Apr 18; 8(8):739-43. PubMed ID: 19242112
    [Abstract] [Full Text] [Related]

  • 14. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.
    Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P.
    Mol Cancer; 2011 Sep 07; 10():110. PubMed ID: 21899728
    [Abstract] [Full Text] [Related]

  • 15. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

  • 16. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.
    Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S.
    Blood; 2009 Nov 12; 114(20):4507-16. PubMed ID: 19773546
    [Abstract] [Full Text] [Related]

  • 17. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S, Sinicrope FA.
    Cancer Res; 2008 Apr 15; 68(8):2944-51. PubMed ID: 18413764
    [Abstract] [Full Text] [Related]

  • 18. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.
    Mol Cancer Ther; 2017 Jan 15; 16(1):102-115. PubMed ID: 27980105
    [Abstract] [Full Text] [Related]

  • 19. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
    Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A.
    Proc Natl Acad Sci U S A; 2006 Oct 03; 103(40):14907-12. PubMed ID: 16997913
    [Abstract] [Full Text] [Related]

  • 20. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
    Song JY, Kim CS, Lee JH, Jang SJ, Lee SW, Hwang JJ, Lim C, Lee G, Seo J, Cho SY, Choi J.
    Invest New Drugs; 2013 Dec 03; 31(6):1458-65. PubMed ID: 24068620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.